Karihtala, P. (2025) “How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?”, Acta Oncologica, 64, pp. 815–829. doi: 10.2340/1651-226X.2025.43645.